A killer mimotope with therapeutic activity against AIDS-related opportunistic micro-organisms inhibits ex-vivo HIV-1 replication

AIDS

Volumn 20, Issue 7, 2006, Pages 975-980

  Casoli, Claudio ^a   Pilotti, Elisabetta ^a   Perno, Carlo Federico ^b   Balestra, Emanuela ^b   Polverini, Eugenia ^a   Cassone, Antonio ^c   Conti, Stefania ^a   Magliani, Walter ^a   Polonelli, Luciano ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Antibodies; Antiretroviral therapy; Opportunistic infections; Receptor; Virus cell interaction

Indexed keywords

ANTIGEN P24; ANTIRETROVIRUS AGENT; BETA 1,6 GLUCAN; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; GLYCOPROTEIN GP 120; KILLER DECAPEPTIDE; PEPTIDE; UNCLASSIFIED DRUG; ZIDOVUDINE;

AIDS RELATED COMPLEX; ANTIGEN DETECTION; ANTIMICROBIAL ACTIVITY; ARTICLE; BINDING AFFINITY; CELL VIABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MICROORGANISM DETECTION; OPPORTUNISTIC INFECTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; VIRUS CELL INTERACTION; VIRUS REPLICATION; VIRUS STRAIN;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DOWN-REGULATION; HIV ENVELOPE PROTEIN GP160; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MOLECULAR MIMICRY; PEPTIDES; RECEPTORS, CCR5; RECEPTORS, CXCR4; RNA, VIRAL; SEQUENCE ALIGNMENT; VIRUS REPLICATION; ZIDOVUDINE;

EID: 33646372487     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000222068.14878.0d     Document Type: Article

References (33)

1. Durden FM, Elewski B. Fungal infections in HIV-infected patients. Semin Cutan Med Surg 1997; 16:200-212.
2. Currier JS. Opportunistic infections in the age of highly active antiretroviral therapy. AIDS Patient Care STDS 1998; 12:521-525.
3. Anon. Opportunistic infections remain a key problem. Comorbid conditions growing in importance. AIDS Alert 2004; 19:139.
4. Polonelli L, Magliani W, Conti S, Bracci L, Lozzi L, Neri P, et al. Therapeutic activity of an engineered synthetic killer antiidiotypic antibody fragment against experimental mucosal and systemic candidiasis. Infect Immun 2003; 71:6205-6212.
5. Cenci E, Bistoni F, Mencacci A, Perito S, Magliani W, Conti S, et al. A synthetic peptide as a novel anticryptococcal agent. Cell Microbiol 2004; 6:953-961.
6. Travassos LR, Silva LS, Rodrigues EG, Conti S, Salati A, Magliani W, et al. Therapeutic activity of a killer peptide against experimental paracoccidioidomycosis. J Antimicrob Chemother 2004; 54:956-958.
7. Magliani W, Conti S, De Bernardis F, Gerloni M, Bertolotti D, Mozzoni P, et al. Therapeutic potential of antiidiotypic single chain antibodies with yeast killer toxin activity. Nat Biotechnol 1997; 15:155-158.
8. Beninati C, Oggioni MR, Boccanera M, Spinosa MR, Maggi T, Conti S, et al. Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria. Nat Biotechnol 2000; 18:1060-1064.
9. Polonelli L, De Bernardis F, Conti S, Boccanera M, Magliani W, Gerloni M, et al. Human natural yeast killer toxin-like candidacidal antibodies. J Immunol 1996; 156:1880-1885.
10. Polonelli L, Séguy N, Conti S, Gerloni M, Bertolotti D, Cantelli C, et al. Monoclonal yeast killer toxin-like candidacidal anti-idiotypic antibodies. Clin Diagn Lab Immunol 1997; 4:142-146.
11. Magliani W, Conti S, Gerloni M, Bertolotti D, Polonelli L. Yeast killer systems. Clin Microbiol Rev 1997; 10:369-400.
12. Séguy N, Cailliez JC, Delcourt P, Conti S, Camus D, Dei-Cas E, et al. Inhibitory effect of human natural yeast killer toxin-like candidacidal antibodies on Pneumocystis carinii. Mol Med 1997; 3:544-552.
13. Conti S, Fanti F, Magliani W, Gerloni M, Bertolotti D, Salati A, et al. Mycobactericidal activity of human natural, monoclonal, and recombinant yeast killer toxin-like antibodies. J Infect Dis 1998; 177:807-811.
14. Conti S, Magliani W, Arseni S, Dieci E, Frazzi R, Salati A, et al. In vitro activity of monoclonal and recombinant yeast killer toxin-like antibodies against antibiotic-resistant gram-positive cocci. Mol Med 2000; 6/7:613-619.
15. Cenci E, Mencacci A, Spreca A, Montagnoli C, Bacci A, Perruccio K, et al. Protection of killer antiidiotypic antibodies against early invasive aspergillosis in a murine model of allogeneic T-cell-depleted bone marrow transplantation. Infect Immun 2002; 70:2375-2382.
16. Guyard C, Dehecq E, Tissier JP, Polonelli L, Dei-Cas E, Cailliez JC, et al. Involvement of β-glucans in the wide-spectrum antimicrobial activity of Williopsis saturnus var. mrakii MUCL 41968 killer toxin. Mol Med 2002; 8:686-694.
17. Savoia D, Avanzini C, Conti S, Magliani V, Frazzi R, Polonelli L. In vitro leishmanicidal activity of a monoclonal antibody mimicking a yeast killer toxin. J Eukaryot Microbiol 2002; 49:319-323.
18. Cole AM, Lehrer RI. Minidefensins: antimicrobial peptides with activity against HIV-1. Curr Pharm Des 2003; 9:1463-1473.
19. Chang TL, Klotman ME. Defensins: natural anti-HIV peptides. AIDS Rev 2004; 6:161-168.
20. Price DA, O'Callaghan CA, Whelan JA, Easterbrook PJ, Phillips RE. Cytotoxic T lymphocytes and viral evolution in primary HIV-1 infection. Clin Sci 1999; 97:707-718.
21. Casoli C, Vicenzi E, Cimarelli A, Magnani G, Ciancianaini P, Cattaneo E, et al. HTLV-II downregulates HIV-1 replication in IL-2 stimulated PBMC cultures of co-infected individuals through expression of MIP-1alpha. Blood 2000; 95:2760-2769.
22. Balzarini J, Aquaro S, Perno CF, Witvrouw M, Holy A, De-Clercq E. Activity of the (R)-enantiomers of 9-(2-phosphonylmethoxypropyl)-adenine and 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine against human immunodeficiency virus in different human cell systems. Biochem Biophys Res Commun 1996; 219:337-341.
23. Aquaro S, Perno CF, Balestra E, Balzarini J, Cenci A, Francesconi M, et al. Inhibition of replication of HIV in primary monocyte/macrophages by different antiviral drugs and comparative efficacy in lymphocytes. J Leukocyte Biol 1997; 62:138-143.
24. Perno CF, Yarchoan R, Cooney DA, Hartman NR, Gartner S, Popovic M, et al. Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocyte/macrophages by azidothymidine and related 2′,3′-dideoxynucleosides. J Exp Med 1988; 168:1111-1125.
25. Kwong PD, Wyatt V, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998; 393:648-659.
26. Kwong PD, Wyatt R, Majeed S, Robinson J, Sweet RW, Sodroski J, et al. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure Fold Des 2000; 8:1329-1339.
27. Cocchi F, DeVico AL, Garzino-Demo A, Cara A, Gallo RC, Lusso P. The V3 domain of the HIV-1 gp 120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat Med 1996; 2:1244-1247.
28. Speck RF, Wehrly K, Platt EJ, Atchison RE, Charo IF, Kabat D, et al. Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop. J Virol 1997; 71:7136-7139.
29. Magliani W, Conti S, Salati A, Arseni S, Ravanetti L, Frazzi R, et al. Engineered killer mimotopes: new synthetic peptides for antimicrobial therapy. Curr Med Chem 2004; 11:1793-1800.
30. Mata-Essayag S, Magaldi S, Hartung-de-Capriles C, Deibis L, Verde G, Perez C. 'In vitro' antifungal activity of protease inhibitors. Mycopathologia 2001; 152:135-142.
31. Blanco MT, Hurtado C, Perez-Giraldo C, Moran FJ, Gonzalez-Velasco C, Gomez-Garcia AC. Effect of ritonavir and saquinavir on Candida albicans growth rate and in vitro activity of aspartyl proteinases. Med Mycol 2003; 41:167-170.
32. Ruhnke M. Mucosal and systemic fungal infections in patients with AIDS: prophylaxis and treatment. Drugs 2004; 64:1163-1180.
33. Humphrey W, Dalkey A, Schulten K. VMD: visual molecular dynamics. J Mol Graph 1996: 14, 33, 38. [http://www.ks.uiuc.edu/Research/vmd].